Clinical trials: Neurocognitive Disorder
Alzheimer's Disease
Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers
This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed either AVA102670 or AVA102672.
- Trial name
- NCT00490568
- Testing
- Rosiglitazone XR
- Where
- 272 sites in United States, Argentina and 27 more
- Volunteers
- 1,461 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
AAB-001 in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate Alzheimer's disease (AD).
- Trial name
- NCT00112073
- Testing
- bapineuzumab
- Where
- 26 sites in United States
- Volunteers
- 234 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Stroke, Attention Disorder
Virtual-reality Exercises for Alleviating Attention Deficits in Patients With Acquired Brain Injury
Stroke is the leading cause of long-term disability with an increasing incidence, especially in young adults. Among the cognitive difficulties following brain damage, deficits in attention are frequent and pervasive, affecting…
- Trial name
- NCT05728840
- Testing
- Immersive virtual reality gamified cognitive activities, Double neuropsychological standard activities
- Where
- Switzerland
- Volunteers
- 135 people
- Sponsor
- Mindmaze SA
Chorea, Huntington
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine to treat chorea in participants with Huntington disease.
- Trial name
- KINECT-HD (NCT04102579)
- Testing
- Valbenazine
- Where
- 46 sites in United States, Canada
- Volunteers
- 128 people
- Sponsor
- Neurocrine Biosciences
Alzheimer's Disease
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease
The purpose of this study is to evaluate the long-term safety and tolerability of Dimebon in patients with Alzheimer's disease.
- Trial name
- NCT00939783
- Testing
- Dimebon
- Where
- 105 sites in United States, Canada and 1 more
- Volunteers
- 649 people
- Sponsor
- Pfizer
Huntington Disease
Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients.
Cellavita-HD is a stem-cell therapy for Huntington's Disease. Open label, single treatment, extension study for long-term safety and efficacy evaluation of Cellavita-HD intravenous administration in Huntington's disease patients…
- Trial name
- ADORE-EXT (NCT04219241)
- Testing
- Cellavita-HD
- Where
- Brazil
- Volunteers
- 35 people
- Sponsor
- Azidus Brasil
Alzheimer Disease
Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease
The primary purpose of this study is to assess biomarker known as amyloid beta peptide 40 (Ab40) in Cerebrospinal Fluid (CSF), following a single oral dose of PAZ-417 in subjects with Alzheimer Disease (AD).
- Trial name
- NCT00739037
- Testing
- PAZ-417
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease
Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance.
- Trial name
- Elevage (NCT03980730)
- Testing
- Azeliragon
- Where
- 33 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- vTv Therapeutics
Alzheimer Disease, Mild Cognitive Impairment
Quality Improvement PrecivityAD Clinician Survey (QUIP I)
There is an important unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and early dementia.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline
- Trial name
- QUIP I (NCT05477056)
- Testing
- PrecivityAD blood test
- Where
- United States
- Volunteers
- 366 people
- Sponsor
- C2N Diagnostics
Alzheimer Disease, Early Onset
A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease
This study is a multicenter, randomized, double-blinded, placebo-controlled Phase 3 study comparing LIPUS-Brain transcranial low-intensity pulsed-wave ultrasound device to placebo in patients with Early Alzheimer's Disease.
- Trial name
- NCT05983575
- Testing
- LIPUS-Brain
- Where
- 19 sites in Japan
- Volunteers
- 220 people
- Sponsor
- Sound Wave Innovation CO., LTD.
Agitation in Patients With Dementia of the Alzheimer's Type
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) was to be based on the "2011 Diagnostic Guidelines for Alzheimer's Disease" issued by the National…
- Trial name
- NCT02442765
- Testing
- AVP-786
- Where
- 126 sites in United States, Estonia and 4 more
- Volunteers
- 387 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Sleep Disorder, Nightmare
Validation of the Sleep Assessment Algorithm in the Medical Application Nightly
The Nightly medical application prototype is a potential, non-invasive class I medical device. The application has the potential to combine both diagnostic and therapeutic procedures for sleep.
- Trial name
- NCT03532269
- Testing
- Nightly App
- Where
- Poland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- DreamJay Sp. z o. o.
Alzheimer Disease
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
This is a randomized double-blind Placebo-controlled, Phase 2 study comparing bryostatin to placebo for the treatment of moderately severe to severe Alzheimer's disease in subjects not receiving memantine treatment.
- Trial name
- NCT03560245
- Testing
- Bryostatin
- Where
- 28 sites in United States
- Volunteers
- 108 people
- Sponsor
- Neurotrope Bioscience, Inc.
Cognitive Disorders
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of SUVN-G3031 in healthy male subjects following single or multiple ascending doses.
- Trial name
- NCT02342041
- Testing
- SUVN-G3031
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Healthy
Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered
The purpose of this study is to evaluate the effects of multiple doses of Gemfibrozil on the plasma concentration of a single dose of SAM-531 in healthy young adult subjects and to assess the safety and tolerability of…
- Trial name
- NCT00966966
- Testing
- SAM-531 and gemfibrozil
- Where
- Netherlands
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease
Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers
The purpose of this study is to examine the safety, tolerability and pharmacokinetics of single and multiple doses of NNI-362 in healthy aged population.
- Trial name
- NCT04074837
- Testing
- NNI-362
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Neuronascent, Inc.
Mild Cognitive Impairment
Effectiveness and Safety of a Digitally Based Multidomain Intervention for Mild Cognitive Impairment
This study is designed to evaluate the preliminary effectiveness and safety of a digitally based multidomain intervention in patients with MCI.
- Trial name
- NCT05059353
- Testing
- Digitally based multidomain intervention
- Where
- Singapore
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Neuroglee Therapeutics
Alzheimer's Disease
Safety and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of CS6253 in Healthy Volunteers
Phase 1A SAD: Five or more cohorts of 8 healthy volunteers (HVs) will receive a single IV bolus injection of study drug or placebo. The first 4 cohorts will be male only.
- Trial name
- NCT05965414
- Testing
- CS6253 Solution for Injection
- Where
- Spain
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Artery Therapeutics, Inc.
Alzheimer Disease
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males
To assess the safety and tolerability of ascending single oral doses of SAM-315, an investigational drug, in healthy Japanese male subjects.To obtain preliminary pharmacokinetic (PK) and pharmacodynamic (PD) profiles of SAM-315…
- Trial name
- NCT00480467
- Testing
- SAM-315
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease, Alzheimer Disease, Early Onset
Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild…
- Trial name
- NCT07221344
- Testing
- ARO-MAPT-SC
- Where
- 4 sites in Canada, New Zealand
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals